RxDoctor Payments Data

Raymund Untalan, MD

Internal Medicine · San Angelo, TXNPI 1275590796

Payments from drug & device makers

$525in general payments, 2019–2025

Across 36 payments — averaging $14.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$250
  • AbbVie$60
  • Boehringer Ingelheim$43
  • Kyowa Kirin, Inc.$41
  • Amarin Pharma, Inc.$38
  • Collaborative Care Diagnostics, LLC$29
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$525100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk18$250
AbbVie4$60
Boehringer Ingelheim3$43
Kyowa Kirin, Inc.2$41
Amarin Pharma, Inc.3$38
Collaborative Care Diagnostics, LLC1$29
Amgen2$28
Lilly USA, LLC1$13
Merck1$11
Sanofi Pasteur Inc.1$11

How this compares

$525 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$173,203
Medicare patients
244
Services billed
2,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$84,893
JanuviaSitagliptin Phosphate73$80,070
OzempicSemaglutide44$48,734
EliquisApixaban22$37,126
MounjaroTirzepatide23$23,389
TrulicityDulaglutide17$15,203
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$11,201
Potassium Chloride183$8,083
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$7,152
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$6,804
Levothyroxine Sodium519$6,103
Icosapent Ethyl17$4,790
CreonLipase/Protease/Amylase12$4,400
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp11$4,293
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$3,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$43$84,89390 claims
MerckJanuvia$11$80,07073 claims
Novo NordiskOzempic$250$48,73444 claims
Lilly USA, LLCMounjaro, Trulicity$13$38,59340 claims
AbbVieCreon, Synthroid$60$5,92792 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →